flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
MDxHealth (R): MDxHealth Shareholder Transparency Declaration
MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), announced that it received on August 3, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act").
argenx to Present at 2018 Wedbush PacGrow Healthcare Conference
argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that the Company will present on Tuesday, August 14th at 1:20 p.m. ET at the 2018 Wedbush PacGrow Healthcare Conference in New York.
Rejuvenate Biomed awarded €460,000 grant from VLAIO to accelerate drug development for healthy aging
CMAST was instrumental in the Grant proposal submission.
Rejuvenate Biomed - a biomedical company that researches the biology of aging and applies this knowledge to identify drugs that delay the aging process – today announces it has been awarded a €460K Research Grant by Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to gain new insights in the aging pathways – which will ultimately contribute to the clinical research and the exploitation of a first lead candidate.